Association between urinary prostaglandin E2 metabolite and breast cancer risk: A prospective, case-cohort study of postmenopausal women

Cancer Prevention Research

Volumn 6, Issue 6, 2013, Pages 511-518

  Kim, Sangmi ^a,b   Taylor, Jack A ^b   Milne, Ginger L ^c   Sandler, Dale P ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PROSTAGLANDIN E2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CASE STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEALTH STATUS; HIP CIRCUMFERENCE; HUMAN; LIFESTYLE; LIPID DIET; MAJOR CLINICAL STUDY; METABOLITE; OBESITY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTAGLANDIN URINE LEVEL; SMOKING; WAIST HIP RATIO;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DINOPROSTONE; FEMALE; HUMANS; LIFE STYLE; MIDDLE AGED; OBESITY; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878887971     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0040     Document Type: Article

References (48)

1. Dunn BK, Wickerham DL, Ford LG. Prevention of hormone-related cancers: breast cancer. J Clin Oncol 2005;23:357-67. (Pubitemid 46209965)
2. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Eng J Med 2001;344:276-85. (Pubitemid 32108534)
3. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-65. (Pubitemid 40081323)
4. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993;15:48-65. (Pubitemid 23269070)
5. Bulun SE, Simpson ER, Berstein LM, Santen RJ. Aromatase expression in women's cancers. Innovative endocrinology of cancer. Chicago, IL: Landes Bioscience and Springer Science+Business Media; 2008. p. 112-32.
6. Endogenous Hormones Breast Cancer Collaborative G. Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk in Postmenopausal Women. JNCI Journal of the National Cancer Institute. 2003;95:1218-26.
7. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17:953-66. (Pubitemid 34020662)
8. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-9.
9. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. In flammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 2011;4:1021-9.
10. Subbaramaiah K, HoweLR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 2011;4:329-46.
11. 2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2:356-65.
12. 2 synthesis and secretion: The role of PGE2 synthases. Clin Immunol 2006;119:229-40.
13. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-42. (Pubitemid 26423150)
14. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008;100:1439-47.
15. Kim S, Sandler DP, Carswell G, De Roo LA, Parks CG, Cawthon R, et al. Telomere length in peripheral blood and breast cancer risk in a prospective case-cohort analysis: results from the Sister Study. Cancer Causes Control 2011;22:1061-6.
16. Weinberg CR, Shore DL, Umbach DM, Sandler DP. Using risk-based sampling to enrich cohorts for endpoints, genes, and exposures. Am J Epidemiol 2007;166:447-55. (Pubitemid 47216791)
17. Seyberth HW, Sweetman BJ, Frolich JC, Oates JA. Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976;11:381-97.
18. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase- specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334:266-75. (Pubitemid 39370961)
19. Fitzgerald DW, Bezak K, Ocheretina O, Riviere C, Wright TC, Milne GL, et al. The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res 2012;5:34-40.
20. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73:1-11.
21. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999;52:1165-72. (Pubitemid 29535416)
22. Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology 2011;22:745.
23. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-93.
24. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclo-oxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-81. (Pubitemid 34408488)
25. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-22. (Pubitemid 41820645)
26. 2 administration. Carcinogenesis 2003;24:985-90.
27. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 2004;6:285-95. (Pubitemid 39222041)
28. Brueggemeier RW, Richards JA, Petrel TA. Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol 2003;86:501-7. (Pubitemid 37412590)
29. Brueggemeier RW, Su B, Sugimoto Y, az-Cruz ES, Davis DD. Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol 2007;106:16-23. (Pubitemid 47362646)
30. 2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol 2006;4:1358-65.
31. Shrubsole MJ, Cai Q, Wen W, Milne G, Smalley WE, Chen Z, et al. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res 2012;5:336-42.
32. Cai Q, Gao YT, Chow WH, Shu XO, Yang G, Ji BT, et al. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncol 2006;24:5010-6. (Pubitemid 46631404)
33. Dong LM, Shu XO, Gao YT, Milne G, Ji BT, Yang G, et al. Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study. Cancer Epidemiol Biomarkers Prev 2009;18:3075-8.
34. Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks L, Dang CT, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging and lung metastases in patients with breast cancer. Cancer Prev Res 2013;6:428-36.
35. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66. (Pubitemid 34196319)
36. Dovizio M, Tacconelli S, Ricciotti E, Bruno A, Maier TJ, Anzellotti P, et al. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. J Pharmacol Exp Ther 2012;341:242-50.
37. Sample D, Wargovich M, Fischer SM, Inamdar N, Schwartz P, Wang X, et al. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev 2002;11:275-9. (Pubitemid 34327005)
38. Gross ND, Boyle JO, Morrow JD, Williams MK, Moskowitz CS, Subbaramaiah K, et al. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 2005;11:6087-93. (Pubitemid 41170341)
39. van Kruijsdijk RCM, van der Wall E, Visseren FLJ. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569-78.
40. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008;68:323-8. (Pubitemid 351380135)
41. Flower RJ, Perretti M. Controlling inflammation: a fat chance? J Exp Med 2005;201:671-4. (Pubitemid 40395111)
42. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 2003;100:1751-6. (Pubitemid 36254520)
43. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4. J Biol Chem 2001;276:16683-9.
44. Wu X, Cai H, Xiang YB, Cai Q, Yang G, Liu D, et al. Intra-person variation of urinary biomarkers of oxidative stress and inflammation. Cancer Epidemiol Biomarkers Prev 2010;19:947-52.
45. Fahmi H. mPGES-1 as a novel target for arthritis. Curr Opin Rheumatol 2004;16:623-7. (Pubitemid 39128335)
46. 2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand 2003;108:125-9.
47. Almer G, Teismann P, Stevic Z, Halaschek-Wiener J, Deecke L, Kostic V, et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 2002;58:1277-9. (Pubitemid 34411875)
48. Kinney JS, Ramseier CA, Giannobile WV. Oral fluid-based biomarkers of alveolar bone loss in periodontitis. Ann N Y Acad Sci 2007;1098:230-51. (Pubitemid 47092549)